GCM
ALXO icon

Graham Capital Management’s ALX Oncology ALXO Stock Holding History

Graham Capital Management’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$155K Buy
74,821
+37,082
+98% +$66.4K ﹤0.01% 1087
2026
Q1 		$75.7K Buy
+37,739
New +$71.9K ﹤0.01% 1069
2024
Q4 		– Sell
-96,849
Closed -$176K – 1212
2024
Q3 		$176K Buy
96,849
+72,907
+305% +$271K ﹤0.01% 940
2024
Q2 		$144K Buy
+23,942
New +$294K ﹤0.01% 902

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Graham Capital Management's ALXO Position: Q2 2026 in Review

Graham Capital Management increased its ALX Oncology (ALXO) stake by 98% in Q2 2026, buying an estimated $66.4K and bringing the position to 74,821 shares worth $155K. The position accounts for ﹤0.01% of the portfolio, ranked #1087.

Graham Capital Management first reported a position in ALXO in Q2 2024 and has held it in 4 quarters since. The position peaked at $176K in Q3 2024. 94 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

  • Graham Capital Management held 74,821 shares of ALX Oncology worth $155K as of Q2 2026.
  • Graham Capital Management bought 37,082 ALX Oncology shares in Q2 2026, an estimated $66.4K.
  • ALX Oncology made up ﹤0.01% of Graham Capital Management's portfolio in Q2 2026, its #1087 holding.
  • Graham Capital Management first reported a position in ALX Oncology in Q2 2024 and has held it in 4 quarters since.
  • Graham Capital Management's ALX Oncology position peaked at $176K in Q3 2024.
  • 94 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.